Found 352 oncology trials
A listing of oncology medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
The purpose of this study is to evaluate how well the study drug (Navitoclax) works in combination with ruxolitinib when compared to best available therapy in subjects with Relapsed/Refractory Myelofibrosis.
This is a phase 1 study evaluating ziftomenib in combination with azacitidine and venetoclax, or standard induction therapy cytarabine/daunorubicin (7+3) or vyxeos chemotherapy for patients who have newly diagnosed or relapse refractory acute myeloid leukemia with KMT2A rearrangement or NPM1 mutation.
This phase III trial compares the effect of usual treatment of chemotherapy (Hyper CVAD) and steroids and a tyrosine kinase inhibitor (TKI) which are Dasatinib or Ponatinib and Blinatumomab to TKIs. B-cell acute lymphocytic leukemia.
NP-G2-044 Monotherapy Primary Objectives The primary objectives for patients receiving NP-G2-044 monotherapy are the following: 1) to identify the recommended Phase 2 dose (RP2D) of continuously dosed NP-G2-044 monotherapy (Mono-RP2D) and characterize its safety; and 2) to assess preliminary signals of NP-G2-044 anti-tumor efficacy when administered as continuously dosed monotherapy.
This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies. We would like to rely on Advarra as the IRB of record for this study.
Please refer to Protocol Section 2 (Objectives and Endpoints). Please refer to Protocol Section 2 (Objectives and Endpoints). Please refer to Protocol Section 2 (Objectives and Endpoints).
Please refer to Protocol Section 4.0 (Objectives and endpoints). Please refer to Protocol Section 4.0 (Objectives and endpoints). Please refer to Protocol Section 4.0 (Objectives and endpoints).
This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, PK, preliminary antitumor activity, and effect of biomarkers of XL092 administered alone, and in combination with nivolumab (doublet), nivolumab + ipilimumab (triplet) and nivolumab + relatlimab (triplet) in subjects with advanced solid tumors.
Subjects will be recruited from the Radiation Oncology and Neurosurgery practices at the Hospital of the University of Pennsylvania. The treating radiation oncologist will determine if the patient is a potential research candidate and has the capacity to consent. The goal of this study is to collect and analyze blood …
Subjects with Stage III resectable melanoma will receive adjuvant therapy, nivolumab or ipilimumab plus nivolumab, based on whether a pathologic complete response (CR) or near CR (less than 10% viable tumor cells) is achieved with one dose of nivolumab in the neoadjuvant setting followed by surgery.
